Compare · NVO vs OBX
NVO vs OBX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Obsidian Therapeutics Inc. (OBX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and OBX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $184.33B, about 237.6x OBX ($775.9M).
- Over the past year, NVO is down 14.1% and OBX is down 59.8% - NVO leads by 45.7 points.
- OBX has been more active in the news (9 items in the past 4 weeks vs 7 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for OBX).
- Company
- Novo Nordisk A/S
- Obsidian Therapeutics Inc.
- Price
- -
- -
- Market cap
- $184.33B
- $775.9M
- 1M return
- +6.11%
- +3.24%
- 1Y return
- -14.12%
- -59.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 9
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Obsidian Therapeutics Inc.
Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian's proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian has offices in Cambridge and Bedford, MA. For more information, please visit www.obsidiantx.com.
Latest NVO
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest OBX
- Director Reisenauer Mark L was granted 75,364 stock options (SEC Form 4)
- SEC Form 3 filed by new insider Reisenauer Mark L
- Chief Financial Officer Feder Julie B was granted 164,790 stock options (SEC Form 4)
- Chief Medical Officer Hari Parameswaran was granted 331,173 stock options (SEC Form 4)
- Amendment: Chief Executive Officer Jagasia Madan was granted 678,477 stock options (SEC Form 4)
- SEC Form 424B3 filed by Obsidian Therapeutics Inc.
- SEC Form 10-Q filed by Obsidian Therapeutics Inc.
- Obsidian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates